Exploring Neuronetics, Inc. (STIM) Investor Profile: Who’s Buying and Why?

Have you ever wondered who is investing in Neuronetics, Inc. (STIM), a company focused on transforming neurohealth with its NeuroStar Advanced Therapy for mental health? With over 4.8 million treatment sessions delivered, and recent news of Evernorth Health Services expanding NeuroStar TMS coverage for adolescents, it's a good time to examine the investors who are shaping its path.

Neuronetics, Inc. (STIM) Who Invests in Neuronetics, Inc. (STIM) and Why?

Understanding the investor profile of Neuronetics, Inc. (STIM) provides valuable insights into the company's market perception and future prospects. A diverse investor base can contribute to stock stability, while concentrated ownership may lead to higher volatility. Here's an exploration of the key investor types, their motivations, and typical investment strategies regarding Neuronetics, Inc. (STIM).

Key Investor Types

Neuronetics, Inc. (STIM) has a mix of different types of investors, including:

• Retail Investors: Individual investors who buy and sell shares for their own accounts.
• Institutional Investors: Entities that invest on behalf of others, such as:
  • Mutual Funds: Pools of money collected from many investors to invest in a diversified portfolio.
  • Hedge Funds: Investment funds that use more aggressive strategies to maximize returns.
  • Pension Funds: Funds that provide retirement income to their members.
  • Insurance Companies: Firms that invest premiums to cover future claims.
  • Investment Banks: Financial institutions that manage and invest capital.

According to Fintel, Neuronetics, Inc. (US:STIM) has 74 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7,823,533 shares.

Some of the major institutional shareholders include:

• Masters Capital Management Llc
• Balyasny Asset Management Llc
• Vanguard Group Inc
• FourWorld Capital Management LLC
• VTSMX - Vanguard Total Stock Market Index Fund Investor Shares
• VEXMX - Vanguard Extended Market Index Fund Investor Shares
• UBS Group AG
• BlackRock, Inc.
• Geode Capital Management, Llc
• HighTower Advisors, LLC

Investment Motivations

Investors are attracted to Neuronetics, Inc. (STIM) for several reasons:

• Growth Prospects: Neuronetics, Inc. (STIM) operates in the neurohealth sector, which has significant growth potential. The company's NeuroStar Advanced Therapy System, a non-invasive treatment for major depressive disorder (MDD), has shown promising results.
• Market Expansion: Neuronetics, Inc. (STIM) is expanding its market reach through new clinical indications, including therapies for adolescents, which increases its total addressable market by 35%.
• Strategic Acquisitions: The acquisition of Greenbrook TMS in December 2024 is expected to drive revenue growth and create cost synergies. The merger aims to create a $145 million revenue entity with potential for mid-teens growth in 2025-2026.
• FDA Clearances: NeuroStar Advanced Therapy received FDA clearance as a first-line adjunct for MDD in adolescents aged 15–21 in March 2025, boosting investor confidence.
• Financial Performance: In 2024, Neuronetics's revenue was $74.89 million, an increase of 4.96% compared to the previous year's $71.35 million.
• Analyst Ratings: According to 4 analysts, the average rating for STIM stock is 'Buy.' The 12-month stock price forecast is $6.0, which is an increase of 55.04% from the latest price.

Investment Strategies

Different investors adopt various strategies when investing in Neuronetics, Inc. (STIM):

• Long-Term Holding: Some institutional investors, like Vanguard Group Inc and BlackRock, Inc., typically hold shares for extended periods, reflecting confidence in the company's long-term growth potential.
• Short-Term Trading: Hedge funds, such as Masters Capital Management Llc and Balyasny Asset Management Llc, may engage in more frequent trading to capitalize on short-term price fluctuations.
• Value Investing: Investors may find Neuronetics, Inc. (STIM) attractive due to its perceived undervaluation. Despite a 430% rally since November 2024, the company's forward P/S ratio of 1.71x is below sector norms, suggesting potential undervaluation.

Here is a summary of key financial data and analyst estimates:

Neuronetics, Inc. is dedicated to enhancing the lives of individuals dealing with psychiatric disorders. With over 4.8 million treatment sessions administered, NeuroStar has significantly impacted numerous lives. The company's dedication is evident through its patient-focused strategy in creating, developing, and promoting products designed to improve the well-being of those affected by mental health conditions.

To gain further insights into Neuronetics, Inc.'s mission, vision, and core values, check out: Mission Statement, Vision, & Core Values of Neuronetics, Inc. (STIM).

Neuronetics, Inc. (STIM) Institutional Ownership and Major Shareholders of Neuronetics, Inc. (STIM)

Institutional ownership in Neuronetics, Inc. (STIM) can significantly influence its stock price and overall market strategy. Examining the major institutional investors and their recent activities provides valuable insights into the market's sentiment towards the company.

As of Q4 2023:

• The total number of institutional owners was 152.
• The total shares held by institutions amounted to 14,348,459.
• The percentage of institutional ownership stood at 52.1%.

Here’s a detailed look at some of the top institutional investors in Neuronetics, Inc. (STIM) based on the latest filings:

Recent changes in ownership among institutional investors can indicate shifts in confidence and future expectations for Neuronetics, Inc. (STIM). For example:

• Some institutions may have increased their holdings, signaling a bullish outlook.
• Conversely, others might have reduced their positions, suggesting concerns about the company's prospects.

These changes can be driven by factors such as company performance, industry trends, and broader economic conditions. Monitoring these shifts is crucial for understanding the evolving dynamics of investor sentiment towards Neuronetics, Inc. (STIM).

Institutional investors play a significant role in shaping the stock price and strategic direction of Neuronetics, Inc. (STIM). Their substantial holdings can lead to:

• Increased trading volume and liquidity.
• Greater scrutiny of company performance and governance.
• Potential influence on key decisions through shareholder votes.

The presence of large institutional investors can also enhance the company's credibility and attract further investment, impacting its long-term growth and stability. To gain more insights into the company's goals, check out: Mission Statement, Vision, & Core Values of Neuronetics, Inc. (STIM).

Neuronetics, Inc. (STIM) Key Investors and Their Impact on Neuronetics, Inc. (STIM)

Understanding the investor profile of Neuronetics, Inc. (STIM) is crucial for grasping the dynamics influencing its stock performance and strategic direction. Key investors can exert considerable influence through their holdings and actions, shaping market perception and corporate decisions. Examining notable investors, their recent activities, and their potential impact provides valuable insights for current and prospective shareholders.

While specific, real-time major investor data and their direct impact on Neuronetics, Inc. (STIM) as of late April 2025 is not available, we can discuss generally how to find this information and what it might mean:

• Identifying Key Investors: Typically, major institutional investors, hedge funds, and activist investors are closely watched. These entities often hold significant stakes in a company.
• Sources of Information: Information regarding major shareholders can be found in SEC filings such as 13F filings, which disclose the holdings of institutional investment managers with over $100 million in assets under management. Other filings like Form 3, 4, and 5 reveal insider transactions.
• Analyzing Investor Influence: The influence of major investors can manifest in several ways:
• Strategic Direction: Large shareholders may engage with the management team to influence corporate strategy, capital allocation, and operational decisions.
• Corporate Governance: Investors can propose changes to the board of directors or advocate for specific governance reforms.
• Stock Performance: Significant buying or selling activity by major investors can impact stock prices, either positively or negatively.

Recent moves by key investors, such as increasing or decreasing their positions, can signal their confidence (or lack thereof) in the company's prospects. Activist investors may publicly advocate for changes they believe will unlock shareholder value, which can lead to significant stock movements and strategic shifts within the company.

For example, if a well-known fund manager or an activist investor announces a substantial stake in Neuronetics, Inc. (STIM), it could attract attention from other investors and potentially drive up the stock price. Conversely, if a major investor significantly reduces their holdings, it could raise concerns about the company's future and lead to a sell-off.

To stay informed about investor activity in Neuronetics, Inc. (STIM), it's essential to regularly monitor SEC filings and reputable financial news sources. This ongoing analysis can help investors make informed decisions based on the actions and sentiments of key players in the market.

Here's a hypothetical example of how key investors might be listed (this is purely illustrative and not based on real-time 2024 or 2025 data for Neuronetics, Inc. (STIM)):

Understanding the financial health of Neuronetics, Inc. (STIM) is also crucial for investors. For further insights, you can explore: Breaking Down Neuronetics, Inc. (STIM) Financial Health: Key Insights for Investors

Neuronetics, Inc. (STIM) Market Impact and Investor Sentiment

Understanding the investor profile and market sentiment surrounding Neuronetics, Inc. (STIM) is crucial for assessing the company's current standing and future potential. Several factors influence how major shareholders perceive the company, how the stock market reacts to significant investor actions, and what insights analysts offer regarding the impact of these investors on Neuronetics' future.

Neuronetics, Inc. is a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Here's an overview of the key elements shaping investor sentiment and market reactions related to Neuronetics:

Investor Sentiment:

• Currently, analysts have a generally positive outlook on Neuronetics.
• The consensus rating for STIM stock is 'Strong Buy'. This is based on ratings from 4 Wall Street analysts.
• Of those analysts, 3 issued a 'buy' rating, with 1 rating the stock as 'hold'.
• In the current month, STIM has received 7 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings.
• Major institutional shareholders include Masters Capital Management Llc, Balyasny Asset Management Llc, and Vanguard Group Inc.
• An analysis of institutional put/call ratios can provide insights into overall sentiment, with put options indicating negative sentiment and call options suggesting positive sentiment.

Recent Market Reactions:

• The stock market has reacted to company announcements and financial results. For example, after Neuronetics reported its fourth-quarter 2024 earnings, the stock rose by 3.99% in pre-market trading, despite the company missing EPS forecasts.
• Recent performance has been volatile. STIM stock has fallen by -4.09% compared to the previous week, and the month change is a -23.78% fall.
• Over the last year Neuronetics, Inc. has showed a 2.65% increase.
• The stock's volatility is notable. STIM stock is 11.65% volatile and has a beta coefficient of 0.93.
• Factors, such as the COVID-19 pandemic, can have a disruptive impact on market stability and affect equity market valuations, leading companies like Neuronetics to adopt rights plans to protect shareholder interests.

Analyst Perspectives:

• Analysts' price targets vary, with an average 12-month price target of $6.83.
• The average price target represents an 81.65% increase from the last price of $3.76.
• The high forecast is $8.00 and a low forecast of $5.50.
• However, it's worth noting that some analysts set inflated price targets due to business incentives.
• Analysts predict EPS loss will shrink to $0.19 in 2026 and become almost breakeven in 2029, while revenue will hit $148 million in fiscal year 2025, almost double the current full-year revenue.

Financial Performance:

• In 2024, Neuronetics's revenue was $74.89 million, an increase of 4.96% compared to the previous year's $71.35 million.
• Losses were -$43.71 million, 44.8% more than in 2023.
• Q4 2024 revenue was up 11% year-over-year to $22.5M, beating estimates.
• The company shipped 46 NeuroStar systems, generating $3.8M in revenue.

Key Developments:

• Neuronetics completed the acquisition of Greenbrook TMS, expanding its treatment network.
• The company set 2025 revenue guidance of $145-$155 million.
• The merger with Greenbrook TMS is projected to create a $145 million revenue entity with potential for mid-teens growth in 2025-2026.
• Neuronetics' entry into the adolescent market expands its total addressable market by 35%, opening new avenues for growth and innovation.

Shareholder Information:

• Neuronetics, Inc. (US:STIM) has 74 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
• These institutions hold a total of 7,823,533 shares.
• Largest shareholders include Masters Capital Management Llc, Balyasny Asset Management Llc, Vanguard Group Inc, FourWorld Capital Management LLC, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, VEXMX - Vanguard Extended Market Index Fund Investor Shares, UBS Group AG, BlackRock, Inc., Geode Capital Management, Llc, and HighTower Advisors, LLC.

The following table summarizes the revisions related to the Greenbrook TMS acquisition:

For additional insights into Neuronetics' mission, vision, and core values, you can explore: Mission Statement, Vision, & Core Values of Neuronetics, Inc. (STIM).